INAB - Kill Leukemia Cells While Preserving Healthy Tissues: Nano-Cap Cancer Focused Firm IN8bio's Preclinical Candidate Shows Potential | Benzinga
Tuesday, IN8bio Inc (NASDAQ:INAB) revealed new preclinical data from its non-signaling gamma-delta T cell-based Chimeric Antigen Receptor-T cell (nsCAR) platform, known as INB-300.
The data showed that INB-300 improved selectivity to target leukemia cells while preserving healthy ones.
The data support the potential for nsCAR to have a wider therapeutic window and to be used to prevent on-target off-tumor killing of healthy tissue that may express the CAR-T target.
The data was presented at the American Association for Cancer Research ...